United Therapeutics (NSDQ:UTHR) today announced first-quarter results that came in well ahead of the consensus forecast.
The Research Triangle Park, N.C.-based company posted profits of $28.3 million, or 61¢ per share, on sales of $379.1 million for the three months ended March 31, 2021, for a -79.4% bottom-line slide on sales growth of 6.4%.
Adjusted to exclude one-time items, earnings per share were $3.49, 55¢ ahead of Wall Street, where analysts were looking for sales of $369 million from the company that develops treatments for a number of diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD).
“2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity pump for Remodulin,” United Therapeutics chairperson & CEO Martine Rothblatt said in a news release. “In addition to these product launches and the potential Tyvaso DPI approval in December, we are progressing our late-stage pipeline with the commencement of the pivotal Teton study of Tyvaso in IPF, continued enrollment of the pivotal Perfect study of Tyvaso in PH-COPD, and the ongoing pivotal Advance studies of ralinepag.”
United Therapeutics did not provide financial guidance for the remainder of 2021.
UTHR shares were unmoved in pre-market trading today.
